Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis (2018)
- Authors:
- USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; TRAINA, FABÍOLA - FMRP ; FENERICH, BRUNA ALVES - FMRP ; ALVES, ANA PAULA NUNES RODRIGUES - FMRP ; FERNANDES, JAQUELINE CRISTINA - FMRP ; RIBEIRO, RENATA SCOPIM - FMRP ; SILVA, JUAN LUIZ COELHO DA - FMRP
- Unidades: ICB; FMRP
- DOI: 10.6061/clinics/2018/e566s
- Subjects: RECEPTORES DE INSULINA; LEUCEMIA; HEMATOPOESE; NEOPLASIAS
- Keywords: Insulin Receptor Substrate; Adaptor Protein; Signal Transduction; Hematopoiesis; Leukemia; Myeloproliferative Neoplasms
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
MACHADO NETO, João Agostinho et al. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, v. 73, n. Suppl 1, 2018Tradução . . Disponível em: https://doi.org/10.6061/clinics/2018/e566s. Acesso em: 18 set. 2024. -
APA
Machado Neto, J. A., Fenerich, B. A., Alves, A. P. N. R., Fernandes, J. C., Scopim-Ribeiro, R., Coelho-Silva, J. L., & Traina, F. (2018). Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 73( Suppl 1). doi:10.6061/clinics/2018/e566s -
NLM
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2024 set. 18 ] Available from: https://doi.org/10.6061/clinics/2018/e566s -
Vancouver
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2024 set. 18 ] Available from: https://doi.org/10.6061/clinics/2018/e566s - NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
- IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells
- Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality
- NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
- Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
- Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells
- Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells
- DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients
- Stathmin 1 expression in plasma cell neoplasms. [Carta]
- IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta]
Informações sobre o DOI: 10.6061/clinics/2018/e566s (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 002959474.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
